Risk Factors for Readmission after Allogeneic Hematopoietic Stem Cell Transplantation and Impact on Overall Survival
Open Access
- 1 March 2015
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 21 (3) , 509-516
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Allogeneic Transplant Physician and Center Capacity in the United StatesTransplantation and Cellular Therapy, 2011
- Thirty-Day Readmission Rates for Medicare Beneficiaries by Race and Site of CareJAMA, 2011
- The performance of US hospitals as reflected in risk‐standardized 30‐day mortality and readmission rates for medicare beneficiaries with pneumoniaJournal of Hospital Medicine, 2010
- Relationship Between Early Physician Follow-up and 30-Day Readmission Among Medicare Beneficiaries Hospitalized for Heart FailureJAMA, 2010
- Hematopoietic Stem Cell TransplantationA Global PerspectiveJAMA, 2010
- Recent National Trends in Readmission Rates After Heart Failure HospitalizationCirculation: Heart Failure, 2010
- Mortality and Readmission for Patients With Heart Failure Among U.S. News & World Report ’s Top Heart HospitalsCirculation: Cardiovascular Quality and Outcomes, 2009
- Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and ReadmissionCirculation: Cardiovascular Quality and Outcomes, 2009
- Rehospitalizations among Patients in the Medicare Fee-for-Service ProgramNew England Journal of Medicine, 2009
- An Administrative Claims Measure Suitable for Profiling Hospital Performance on the Basis of 30-Day All-Cause Readmission Rates Among Patients With Heart FailureCirculation: Cardiovascular Quality and Outcomes, 2008